CMS launched a voluntary payment model intended to expand Medicare coverage of GLP‑1 weight‑loss drugs for eligible beneficiaries. The administration designed the pilot to test payment approaches and patient access pathways, aiming to lower cost barriers for a class of medicines that has reshaped obesity care. The plan will enroll participating providers and payers to evaluate utilization, clinical outcomes, and budget impact. Stakeholders including health plans, manufacturers and provider groups will be required to report outcomes and cost metrics under the model; CMS framed the program as a step to inform longer‑term coverage decisions. The pilot’s scope and voluntary nature mean uptake and measurable impact will hinge on enrollment incentives and program design, which CMS said it will monitor closely. For industry watchers: the model signals federal willingness to experiment with novel payment structures for high‑demand biologics and GLP‑1s specifically.